DOVER, Del. — Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the completion of a single ascending dose Phase 1 clinical study of lomonitinib and initiation of a multiple ascending...
Latest News
DOVER, Del. — Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the clearance from the Human Research Ethics Committee in Australia to begin human dosing in the Phase 1 clinical...
TOKYO & NEW YORK – Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed...
Tokyo and Cambridge, Mass. — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and...
Data include the first presentation of results from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA and LENVIMA plus everolimus WOODCLIFF LAKE, N.J., Jan. 27, 2021 – Eisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These...
The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancers that progressed on prior endocrine and targeted therapies, according to results from the...
Stealth BioTherapeutics is planning a Phase 2a clinical trial of elamipretide (SS-31) as a treatment for people with vision loss and/or heart disease associated with Friedreich’s ataxia (FA). The company expects to use data from this study — planned to start later this year — in designing a pivotal clinical...
SOUTH SAN FRANCISCO, Calif. — Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced it will present two posters on the ELA026 clinical program in secondary hemophagocytic lymphohistiocytosis (sHLH) at the 67th American Society of Hematology (ASH) Annual Meeting...
SOUTH SAN FRANCISCO, Calif. — Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that ELA026 has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation (BTD) and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the...
In patients with cystic fibrosis (CF) and Phe508del–gating or Phe508del–residual function genotypes, the use of elexacaftor (ELX)-tezacaftor (TEZ)-ivacaftor (IVA) triple therapy has demonstrated safety and efficacy, conferring additional benefits relative to prior cystic fibrosis transmembrane conductance regulator (CFTR) modulators. These were among the results of research recently published in The New England Journal of...